Abstract
The analysis of circulating tumor DNA (ctDNA) has multiple uses in oncology. In the past few years, studies with vary-ing designs, methods, and quality have emerged that show promise for the use of ctDNA as a tool to detect minimal residual disease (MRD) across luminal gastrointestinal malignancies. This review of the current literature looks at ctDNA in relation to detecting MRD, predicting patient prognosis, and assessing risk for recurrence.
Original language | English (US) |
---|---|
Pages (from-to) | 444-455 |
Number of pages | 12 |
Journal | Clinical Advances in Hematology and Oncology |
Volume | 20 |
Issue number | 7 |
State | Published - Jul 2022 |
Keywords
- Circulating tumor DNA
- MRD
- gastrointestinal cancer
- prognosis
- residual disease
ASJC Scopus subject areas
- Hematology
- Oncology